A study involving 32 clinical samples from DLBCL found that rH inhibited the M2-type polarization and modulated PAR-1, influencing tumor progression, but there are no ongoing clinical trials specifically for lymphoma treatment. The gene discussed is F2R; the disease is neoplasm.